Roivant Sciences Reports Financial Results – Revenue Decline & R&D Expense Surge

By Greg Peters • Thursday, May 29 15:19 • Permanent Link

Roivant Sciences, a biopharmaceutical company, has reported its financial results for the years ended March 31, 2025, 2024, and 2023. The company's revenue decreased from $32,713,000 in 2024 to $29,053,000 in 2025, a change of $3,660,000. However, there was an increase in revenue from 2023 to 2024, with a change of $1,183,000.

The cost of revenues decreased from $1,599,000 in 2024 to $911,000 in 2025, a change of $688,000. Similarly, the cost of revenues decreased from $3,034,000 in 2023 to $1,599,000 in 2024, a change of $1,435,000.

Research and development expenses increased from $439,909,000 in 2024 to $550,413,000 in 2025, a change of $110,504,000. However, there was a decrease in research and development expenses from 2023 to 2024, with a change of $14,153,000.

The acquired in-process research and development expenses were $26,450,000 in 2024 and $97,749,000 in 2023, with no expenses reported in 2025.

The company recognized a gain on the sale of Telavant net assets of $110.4 million for the pro-rata portion of the one-time milestone consideration during the year ended March 31, 2025, and approximately $5.3 billion for the sale of the entire equity interest in Telavant during the year ended March 31, 2024.

Roivant Sciences reported a net loss attributable to noncontrolling interests, which consists of the portion of the net loss of those consolidated entities that is not allocated to the company. The net loss attributable to noncontrolling interests was recorded equal to the noncontrolling interest’s proportionate share of the respective operations.

The company's financial report also includes details on interest income, income tax expense, income (loss) from discontinued operations, and change in fair value of investments and liability instruments.

These figures provide a detailed insight into Roivant Sciences' financial performance and the factors contributing to its results of operations for the stated periods. Today the company's shares have moved 6.83% to a price of $11.345. For the full picture, make sure to review Roivant Sciences's 10-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.